Infectious Diseases (all articles)
Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection
20 May, 2021 | 08:52h | UTCCommentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP
A pharmacist-led penicillin allergy assessment program can delabel many “penicillin allergic” patients through allergy histories and penicillin skin testing. The program was associated with reduced use of high Clostridioides difficile infection–risk antibiotics.
20 May, 2021 | 08:30h | UTC
Commentaries on Twitter
🆕💥💥 @jamanetworkopen
Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a 3ry Care Hospital
Phase 1 : Allergy histories
Phase 2 :Allergy histories +Penicillin Skin Testing #IDTwitter https://t.co/pZfVf8TJIn pic.twitter.com/2VvnaCayqj— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) May 13, 2021
This cross-sectional study found pharmacist-driven allergy assessments may help improve antibiotic selection and clinical outcomes for patients and hospitals https://t.co/io5LcU9U9U
— JAMA Network Open (@JAMANetworkOpen) May 13, 2021
M-A: Compared to cefazolin alone, pre-incision cefazolin + adjunctive prophylaxis with macrolides or metronidazole significantly reduces the incidence of post-cesarean surgical site infection and hospital stay.
20 May, 2021 | 08:19h | UTCPre-incision Adjunctive Prophylaxis for Cesarean Sections: A Systematic Review and Meta-analysis – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)
[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.
19 May, 2021 | 08:51h | UTC
Commentary on Twitter (thread – click for more)
RECOVERY pre-print: Colchicine
11340 patients hospitalised with COVID-19
Randomised to colchicine vs usual care
No significant improvement in:
– 28-day mortality
– discharge alive at 28 days
– progression to invasive mechanical ventilation or deathhttps://t.co/mEtYq2qwkL pic.twitter.com/B0MNJWDi6e— Martin Landray (@MartinLandray) May 18, 2021
Perspective | Covid-19: What should we do about B.1.617.2? A classic case of decision making under uncertainty.
19 May, 2021 | 08:48h | UTC
SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment.
19 May, 2021 | 08:49h | UTCSARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment – Cell Metabolism
Commentary on Twitter
A new report reinforces the capability for #SARSCoV2 to infect and kill pancreatic β-islet cells, affect insulin secretion https://t.co/4tpIVNpjTf @Cell_Metabolism #diabetes @StanfordMed @stanfordimmuno @UCSF and collaborators pic.twitter.com/dG027CXS5e
— Eric Topol (@EricTopol) May 18, 2021
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
19 May, 2021 | 08:47h | UTCInternational COVID-19 trial to restart with focus on immune responses – Nature
Opinion | Vaccinating children before poor morally wrong, Oxford scientist says.
19 May, 2021 | 08:44h | UTCVaccinating children before poor morally wrong, Oxford scientist says – BBC
Related: WHO: Wealthy nations urged to delay youth Covid vaccines, donate to solidarity scheme AND Editorial: Vaccinating children against SARS-CoV-2 – “Hard to justify right now for most children in most countries”. AND Opinion | American Kids Can Wait – “The U.S. should delay shots for children until global vaccine-manufacturing capacity significantly expands and the crisis in India subsides”.
Former CDC director: Direct Covid-19 vaccines to where they’re needed most.
19 May, 2021 | 08:42h | UTCFormer CDC director: Direct Covid-19 vaccines to where they’re needed most – CNN
Commentary on Twitter
Vaccine inequity is a serious problem ethically and epidemiologically. Read my latest at @CNN on why we must direct Covid vaccines to where they’re needed the most. https://t.co/2CD5xzI00h
— Dr. Tom Frieden (@DrTomFrieden) May 17, 2021
Review: Testing at scale during the COVID-19 pandemic.
19 May, 2021 | 08:45h | UTCTesting at scale during the COVID-19 pandemic – Nature Reviews Immunology
Commentary on Twitter
🆕💥 @NatureRevGenet
Testing at scale during the COVID-19 pandemic
💥Changes in modes of testing across a generalized COVID-19 infectious course💥
✨Excellent Figure ✨ https://t.co/sUZjRr1gQR pic.twitter.com/ZiOXCw7en2— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) May 10, 2021
M-A: Encephalitis as Neurological Complication of COVID‐19.
19 May, 2021 | 08:41h | UTC
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.
19 May, 2021 | 08:37h | UTC
Commentary on Twitter
📢New ACG Clinical Guideline on Prevention, Diagnosis & Treatment of C. difficile Infections
Focus on clinical challenges – diagnostic issues in diarrhea, distinguishing C. diff colonization from active infection + eval/mgmt of CDI in IBD
Full guideline: https://t.co/QTCzeLB9Ri pic.twitter.com/mqZUN4r4jA
— AJG – The American Journal of Gastroenterology (@AmJGastro) May 18, 2021
[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups.
18 May, 2021 | 08:04h | UTCTherapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv
Commentary on Twitter
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. https://t.co/TkhGs5qow5
— Ryan Zarychanski (@RZarychanski) May 17, 2021
#ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.
18 May, 2021 | 08:01h | UTCAntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology
Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD
More flexible storage conditions for BioNTech/Pfizer’s COVID-19 vaccine. – “This change extends the approved storage period of the unopened thawed vial at 2-8°C (i.e. in a normal fridge after taking out of deep-freeze conditions) from five days to one month”.
18 May, 2021 | 07:59h | UTCMore flexible storage conditions for BioNTech/Pfizer’s COVID-19 vaccine – European Medicines Agency
Commentary: EU Regulator Backs Month-Long Storage of Pfizer COVID-19 Vaccine in Fridges – U.S. News/Reuters
Commentary on Twitter
EMA has changed the recommended storage conditions for Pfizer vaccine. Instead of 5 days the thawed, unopened vials can now be stored in a normal fridge for a month. 👏 https://t.co/MVkDJRQn4b
— Kai Kupferschmidt (@kakape) May 17, 2021
COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.
18 May, 2021 | 07:56h | UTCCOVID vaccines can block variant hitting Asia, lab study finds – Nature
See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress
Commentary on Twitter
Pfizer & Moderna mRNA vaccines are effective against multiple SARSCoV2 variants, including the B.1.617 & B.1.618, 2 variants underlying the surge in India. The research, while not yet peer-reviewed, was conducted at NYU School of Medicine in New York City https://t.co/3ziRhk8f4t pic.twitter.com/VzYQKWqyQF
— delthia ricks 🔬 (@DelthiaRicks) May 17, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
18 May, 2021 | 07:52h | UTC
M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.
18 May, 2021 | 07:50h | UTC
Cohort study finds racial minorities face more severe COVID-19 outcomes.
18 May, 2021 | 07:44h | UTCRacial minorities face more severe COVID-19 outcomes – CIDRAP
Priorities for COVID-19 research response and preparedness in low-resource settings.
18 May, 2021 | 07:46h | UTCPriorities for COVID-19 research response and preparedness in low-resource settings – The Lancet
Analysis: Where are we with drug treatments for covid-19?
18 May, 2021 | 07:47h | UTCWhere are we with drug treatments for covid-19? – The BMJ
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
17 May, 2021 | 08:56h | UTCInvited commentary: Convalescent plasma in patients hospitalised with COVID-19
Commentaries on Twitter
Convalescent plasma:
Yet another example of
Don’t guess, don’t gamble
Randomize… and learn
I’ve heard it said that it was deemed “too difficult” to do a randomised controlled trial. Really? If that’s the case, we must (and can) fix that problem. Pts deserve better. https://t.co/zxIiK5U63v
— Martin Landray (@MartinLandray) May 15, 2021
NEW #COVID19 research—In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Read https://t.co/7Sbe8V9THp. #RECOVERY #RECOVERYtrial pic.twitter.com/D0OLZKxZc4
— The Lancet (@TheLancet) May 16, 2021
[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.
17 May, 2021 | 08:53h | UTCCommentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre
Disease surveillance for the COVID-19 era: time for bold changes.
17 May, 2021 | 08:54h | UTCDisease surveillance for the COVID-19 era: time for bold changes – The Lancet
Commentary on Twitter
https://twitter.com/Chikwe_I/status/1393544947970760707
Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions.
17 May, 2021 | 08:51h | UTCCommentaries: Expert reaction to study looking at the public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines – Science Media Centre AND Delaying second Covid vaccine doses can save lives, study finds – The Guardian AND Delaying second COVID vaccine dose may prevent deaths under certain conditions – The BMJ